The oral solid dosage pharmaceutical formulation market size has grown strongly in recent years. It will grow from $618.34 billion in 2024 to $659.54 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to chronic disease prevalence, aging population, healthcare access expansion, generic formulation promotion, and consumer preference shift.
The oral solid dosage pharmaceutical formulation market size is expected to see strong growth in the next few years. It will grow to $842.15 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to personalized medicine demand, controlled-release adoption, biopharmaceutical focus, emerging market expansion, and policy and reimbursement changes. Major trends in the forecast period include personalized medicine adoption, digital health integration, the rise of telemedicine services, focus on preventive healthcare, and continued expansion of artificial intelligence in healthcare.
The growing prevalence of chronic diseases is expected to drive the expansion of the oral solid dosage pharmaceutical formulation market. Chronic diseases are long-term health conditions that persist for an extended period, typically lasting three months or more. Factors such as aging populations, sedentary lifestyles, poor dietary habits, environmental influences, and advances in detection and diagnosis are contributing to the rise in chronic diseases. Oral solid dosage formulations play a crucial role in chronic disease management, as they are convenient, stable, and provide precise dosing, which supports long-term treatment adherence. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, projected over 35 million new cancer cases by 2050, marking a 77% increase from the estimated 20 million cases in 2022. Therefore, the increasing prevalence of chronic diseases is a key driver of growth in the oral solid dosage pharmaceutical formulation market.
Key players in the oral solid dosage pharmaceutical formulation market are focusing on developing innovative products, such as liquid-filled capsules, to improve drug delivery, enhance bioavailability, and provide more convenient dosing options for patients. Liquid-filled capsules, a type of oral dosage form comprising a gelatin shell filled with a liquid or semi-solid formulation containing active pharmaceutical ingredients (APIs) and excipients, offer advanced delivery systems with enhanced bioavailability and absorption rates. For example, Zeon Lifesciences Ltd., an India-based pharmaceutical company, introduced liquid-filled capsules in July 2023, featuring an innovative delivery system that ensures optimal levels of active ingredients for maximum efficacy and immediate results. These capsules provide precise and consistent dosages, promoting patient compliance and control over medication administration, thus setting a new standard for patient care and compliance in the pharmaceutical industry.
In March 2024, Roquette Frères, a France-based food company, acquired IFF Pharma Solutions for $2.85 billion. This strategic acquisition strengthens Roquette's position in the pharmaceutical industry, expands its product range, enhances formulation capabilities, and fortifies its global presence, positioning the company as a key player in innovative drug delivery solutions. IFF Pharma Solutions, a US-based company providing pharmaceutical solutions including tablets and capsules, complements Roquette's objectives, offering synergistic opportunities for growth and innovation.
Major companies operating in the oral solid dosage pharmaceutical formulation market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc., Novartis AG, Hoffman-La-Roche Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim GmbH, Gilead Sciences, Amgen Inc., Teva Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Biogen Inc., Lonza Group, Catalent Inc., Ashland Inc., Piramal Pharma Solutions, Jubilant Pharmova, CordenPharma International.
North America was the largest region in the oral solid dosage pharmaceutical formulation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral solid dosage pharmaceutical formulation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oral solid dosage pharmaceutical formulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Oral solid dosage pharmaceutical formulations are medications designed to be taken orally in a solid form. These formulations are intended to be ingested and then dissolved or dispersed in the gastrointestinal tract, allowing the active pharmaceutical ingredients (APIs) to be absorbed into the bloodstream, thereby exerting their therapeutic effects. They represent a fundamental aspect of modern medicine, providing a dependable, convenient, and efficacious means of drug delivery.
The primary dosage forms of oral solid dosage pharmaceutical formulations include tablets, capsules, powders and granules, lozenges and pastilles, and gummies. Tablets are solid oral dosage forms created by compressing powdered active ingredients and excipients into a compact, easily ingestible shape. These formulations may incorporate various release mechanisms such as controlled release, immediate release, and delayed release. They are distributed through various channels including hospital pharmacies, retail pharmacies, drug stores, online pharmacies, and hypermarkets or supermarkets, and are utilized by a diverse range of end-users including large, medium, and small-sized companies, among others.
The oral solid dosage pharmaceutical formulation market research report is one of a series of new reports that provides oral solid dosage pharmaceutical formulation market statistics, including oral solid dosage pharmaceutical formulation industry global market size, regional shares, competitors with an oral solid dosage pharmaceutical formulation market share, detailed oral solid dosage pharmaceutical formulation market segments, market trends and opportunities, and any further data you may need to thrive in the oral solid dosage pharmaceutical formulation industry. This oral solid dosage pharmaceutical formulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The oral solid dosage pharmaceutical formulation market consists of sales of chewable tablets, multivitamin tablets, aspirin tablets, probiotic capsules, and protein powders. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Oral Solid Dosage Pharmaceutical Formulation Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on oral solid dosage pharmaceutical formulation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for oral solid dosage pharmaceutical formulation ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oral solid dosage pharmaceutical formulation market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Dosage Form: Tablets; Capsules; Powders and Granules; Lozenges and Pastilles; Gummies2) By Mechanism: Controlled-Release; Immediate-Release; Delayed-Release
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Drug Stores; Online Pharmacies; Hypermarkets or Supermarkets
4) By End-User: Large-Size Companies; Medium and Small-Size Companies; Other End-Users
Subsegments:
1) By Tablets: Immediate-Release Tablets; Extended-Release Tablets; Controlled-Release Tablets; Effervescent Tablets; Chewable Tablets; Sublingual Tablets2) By Capsules: Hard Gelatin Capsules; Soft Gel Capsules; Liquid-Filled Capsules; Delayed-Release Capsules
3) By Powders and Granules: Oral Powders (Reconstitution); Granules (Oral Suspension or Dispersible Granules)
4) By Lozenges and Pastilles: Medicinal Lozenges; Herbal Lozenges; Sugar-Free Lozenges; Pastilles ( Throat or Cough Relief)
5) By Gummies: Vitamin Gummies; Herbal and Nutritional Supplement Gummies; Pharmaceutical Gummies ( Pain Relief or Sleep Aids)
Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Oral Solid Dosage Pharmaceutical Formulation market report include:- Pfizer Inc.
- Johnson & Johnson
- Merck & Co. Inc.
- AbbVie Inc.
- Bayer AG
- Bristol-Myers Squibb Company
- AstraZeneca Plc.
- Novartis AG
- Hoffman-La-Roche Ltd.
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Boehringer Ingelheim GmbH
- Gilead Sciences
- Amgen Inc.
- Teva Pharmaceuticals
- Otsuka Pharmaceutical Co. Ltd.
- Astellas Pharma Inc.
- Biogen Inc.
- Lonza Group
- Catalent Inc.
- Ashland Inc.
- Piramal Pharma Solutions
- Jubilant Pharmova
- CordenPharma International
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | April 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 659.54 Billion |
Forecasted Market Value ( USD | $ 842.15 Billion |
Compound Annual Growth Rate | 6.3% |
Regions Covered | Global |
No. of Companies Mentioned | 24 |